Neuropsychologic Assessments of Dupilumab-Treated Adolescent Participants With Moderate-to-Severe Atopic Dermatitis
(NEURADAD Trial)
Trial Summary
What is the purpose of this trial?
This trial aimed to measure cognitive deficits in adolescents with moderate-to-severe eczema and see if these improved with a specific treatment. The study concluded after the initial phase, which only measured cognitive deficits without starting the treatment phase. The treatment is approved for patients over 12 years with conditions like atopic dermatitis and asthma.
Do I need to stop taking my current medications for this trial?
The trial requires that you stop taking certain medications, such as specific ADHD medications and systemic antihistamines, before participating. If you are using a stable prescription topical medication for AD, you should continue it for at least 2 weeks before the trial.
What safety data exists for dupilumab treatment?
Dupilumab is generally considered safe, but some people may experience side effects like injection site reactions, conjunctivitis (eye inflammation), headaches, and nasopharyngitis (cold-like symptoms). There may be differences in how men and women experience these side effects, with some being more common in one gender.12345
How is the drug dupilumab different from other treatments?
Research Team
Clinical Trial Management
Principal Investigator
Regeneron Pharmaceuticals
Eligibility Criteria
Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Assessment
Participants undergo neuropsychologic assessments using Conners' Continuous Performance Test 3rd Edition (CPT-3) and other measures
Follow-up
Participants are monitored for safety and effectiveness after assessment
Treatment Details
Interventions
- dupilumab
Find a Clinic Near You
Who Is Running the Clinical Trial?
Regeneron Pharmaceuticals
Lead Sponsor
Leonard Schleifer
Regeneron Pharmaceuticals
Chief Executive Officer since 1988
MD and PhD in Medicine
George Yancopoulos
Regeneron Pharmaceuticals
Chief Medical Officer since 1997
MD from Harvard Medical School
Sanofi
Industry Sponsor
Paul Hudson
Sanofi
Chief Executive Officer since 2019
Degree in Economics from Manchester Metropolitan University
Christopher Corsico
Sanofi
Chief Medical Officer
MD from Cornell University, MPH in Chronic Disease Epidemiology from Yale University